Andrew Schmidt

6PUBLICATIONS
62CO-AUTHORS
Haematological tumoursPredictive and prognostic markersSolid tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 10, 2026
A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma.

|Mar 09, 2022
Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19.

Samuel M Rubinstein, Divaya Bhutani, Ryan C Lynch

|Nov 20, 2020
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.

Bradley Alexander McGregor, Matthew T Campbell, Wanling Xie

|Sep 24, 2020
Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.

Andrew Schmidt, Angelyn Anton, Julia Shapiro

|Jun 11, 2020
Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE).

Elizabeth Ahern, Michael J Allen, Andrew Schmidt

Pageof 1

Frequent Collaborators

1 joint publications

Bradley Alexander McGregor

1 joint publications

Mehmet A Bilen

1 joint publications

Rana R McKay

1 joint publications

Toni K Choueiri